203 related articles for article (PubMed ID: 17392299)
1. The demise of the blockbuster?
Cutler DM
N Engl J Med; 2007 Mar; 356(13):1292-3. PubMed ID: 17392299
[No Abstract] [Full Text] [Related]
2. Vertical integration: the drug industry and prescription benefits managers.
Gibaldi M
Pharmacotherapy; 1995; 15(3):265-71. PubMed ID: 7667161
[No Abstract] [Full Text] [Related]
3. Who's really raising drug prices?
Zagorin A
Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
[No Abstract] [Full Text] [Related]
4. Meeting resistance. Express Scripts-Medco deal called anti-competitive.
Lee J
Mod Healthc; 2011 Aug; 41(32):10-1. PubMed ID: 21879692
[No Abstract] [Full Text] [Related]
5. Are we living in the end of the blockbuster drug era?
Debnath B; Al-Mawsawi LQ; Neamati N
Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
[TBL] [Abstract][Full Text] [Related]
6. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
7. Patent nonsense: evidence tells of an industry out of social control.
Mintzberg H
CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
[No Abstract] [Full Text] [Related]
8. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
Latham SR
J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
[No Abstract] [Full Text] [Related]
9. Can price and regulatory controls replace free market competition in the drug industry?
Buc NL; Levitt GM
Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
[No Abstract] [Full Text] [Related]
10. America's pharmaceutical research companies: keeping the cost of health care down. Pharmaceutical Manufacturers Association.
Hawaii Med J; 1992 Jan; 51(1):15-16, 19. PubMed ID: 1740387
[No Abstract] [Full Text] [Related]
11. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
12. State and federal government mandates are changing the face of pharmacy management.
Giaquinta D
Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
[No Abstract] [Full Text] [Related]
13. Prescription drug pricing: the consumer perspective.
Searing A
N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
[No Abstract] [Full Text] [Related]
14. The pharmaceutical industry--to whom is it accountable?
Summers WK; Driscoll J; Orient JM
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
[No Abstract] [Full Text] [Related]
15. Rx: Canadian drugs.
Bugden S
N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15014193
[No Abstract] [Full Text] [Related]
16. The new drug war.
Parloff R
Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428
[No Abstract] [Full Text] [Related]
17. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
Sturm AC
Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
[No Abstract] [Full Text] [Related]
18. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
19. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
20. Rx: higher prices.
Kosterlitz J
Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
